How Depression Is Diagnosed and Treated in Clinical Practice

The World's Leading Cause of Disability

The World Health Organization identifies depression as the leading cause of disability worldwide, affecting approximately 280 million people as of 2023 data — 5% of the global adult population. Each year, approximately 700,000 people die by suicide, a significant proportion attributable to depressive disorders. The economic cost is staggering: the WHO estimated that depression and anxiety disorders cost the global economy $1 trillion per year in lost productivity. Despite this burden, fewer than 50% of people with depression receive effective treatment, and in low-income countries that figure falls below 10%. Understanding how depression is clinically defined and what treatments actually work is essential context for this global health challenge.

Diagnostic Criteria: Major Depressive Disorder

Depression is not simply sadness. The DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) defines Major Depressive Disorder (MDD) as five or more of the following symptoms, present during the same two-week period, representing a change from previous functioning, with at least one symptom being either depressed mood or loss of interest/pleasure (anhedonia):

• Depressed mood most of the day, nearly every day
• Markedly diminished interest or pleasure in all or almost all activities (anhedonia)
• Significant weight change (more than 5% in a month) or change in appetite
• Insomnia or hypersomnia nearly every day
• Psychomotor agitation or retardation observable by others
• Fatigue or loss of energy nearly every day
• Feelings of worthlessness or excessive, inappropriate guilt
• Diminished ability to think, concentrate, or make decisions
• Recurrent thoughts of death, suicidal ideation, or suicide attempt

Symptoms must cause clinically significant distress or functional impairment and must not be attributable to substance use, medication, or another medical condition. The diagnosis is clinical — no biomarker or blood test currently meets diagnostic utility thresholds.

Severity Classification

Neurobiology of Depression

The monoamine hypothesis — that depression results from deficiency of serotonin, norepinephrine, and/or dopamine — emerged from the observation that drugs that deplete monoamines (reserpine) cause depression, while drugs that increase them (MAOIs, tricyclics) treat it. This hypothesis drove antidepressant development for 50 years. It remains partially valid but incomplete.

More recent models emphasize neuroplasticity. Research by Ronald Duman at Yale showed that stress reduces brain-derived neurotrophic factor (BDNF) levels in the hippocampus and prefrontal cortex, causing dendritic retraction and reduced synaptic connectivity. Effective antidepressant treatment — regardless of mechanism — restores BDNF and promotes synaptogenesis. This explains the 2–6 week delay before clinical response to antidepressants: time is required for structural synaptic changes, not merely chemical rebalancing.

Neuroendocrine research consistently finds HPA axis hyperactivity in depression: elevated cortisol, blunted response to dexamethasone suppression, and reduced hippocampal volume (the hippocampus is particularly vulnerable to glucocorticoid toxicity). Inflammatory markers — elevated CRP, IL-6, TNF-alpha — are present in approximately 30% of depressed patients, suggesting inflammatory pathology in a subtype.

Antidepressant Pharmacotherapy

Treatment-Resistant Depression and Advanced Therapies

Treatment-resistant depression (TRD) is defined as failure to respond to at least two adequate antidepressant trials. Approximately 30% of MDD patients meet TRD criteria. Several advanced interventions target this population:

• Electroconvulsive therapy (ECT): response rates of 60–80% in TRD; used for severe, psychotic, or suicidal depression; administered under anesthesia; retrograde amnesia is the main adverse effect
• Transcranial Magnetic Stimulation (TMS): repetitive magnetic pulses over the left dorsolateral prefrontal cortex increase activity in this underactive region; FDA-cleared; response rate approximately 50% in TRD; no systemic side effects
• Esketamine (Spravato): the S-enantiomer of ketamine; FDA-approved nasal spray for TRD (2019); the first new antidepressant mechanism in 30 years; blocks NMDA glutamate receptors, causing rapid (hours) antidepressant effects through BDNF-dependent synaptogenesis; administered under medical supervision due to dissociative effects
• Lithium augmentation: adding lithium to antidepressants achieves response in 40–50% of TRD patients; also the most effective known antisuicidal treatment

This article is for informational purposes only. Consult a qualified healthcare professional for medical advice.